Monday, April 25, 2022 Daily Archives

Danaher and Sartorius: COVID just one variable affecting bioprocess growth

by

Comments from J&J have led to questions surrounding the long-term revenues from COVID-19 vaccines. However, the sector is just one area driving bioprocess growth, both Danaher and Sartorius say. While the COVID-19 virus is still virulent in some areas, the rapid development, scale-up, and delivery of vaccines over the past two years has helped bring the world back to some sense of normality. The unprecedented roll-out has resulted in hundreds-of-billions of dollars ending up in the pockets of several vaccine…

April 25, 2022

Regeneron forks out $250m to buy Checkmate Pharmaceuticals

by

Regeneron will increase its research efforts in immuno-oncology through the all-cash acquisition of Checkmate Pharmaceuticals. Under the terms of the deal, Regeneron will buy Checkmate at an all-cash price of $10.50 per share of its common stock, which places the proposed acquisition at a total equity value of around $250 million. Checkmate is a clinical-stage biopharmaceutical firm focused on developing technology to treat cancer. Its lead investigational candidate is an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 (TLR9) delivered in…

April 25, 2022

Seagen building $400m WA manufacturing plant

by

Seagen will spend between $350 and $400 million over the next three years to construct a greenfield biomanufacturing site in Everett, Washington. Antibody-drug conjugate (ADC) pioneer Seagen (previously Seattle Genetics) will imminently begin constructing a biologics facility in Everett, Washington, close to its existing site in Bothell. The 270,000 square-foot plant is expected to be operational in 2024 and will employ up to 200 workers to produce clinical and commercial products. “In cancer research and development, Seagen must continue to…

April 25, 2022